Cargando…

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia

BACKGROUND AND OBJECTIVES: Patients with spinal cord injury (SCI) commonly experience central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for peripheral neuropathic pain, but evidence for CNeP is lacking. METHODS: This randomized, double-blind, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ushida, Takahiro, Katayama, Yoichi, Hiasa, Yoichi, Nishihara, Makoto, Tajima, Fumihiro, Katoh, Shinsuke, Tanaka, Hirotaka, Maeda, Takeshi, Furusawa, Kazunari, Richardson, Mary, Kakehi, Yoshihiro, Kikumori, Kunika, Kuroha, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074464/ https://www.ncbi.nlm.nih.gov/pubmed/36517235 http://dx.doi.org/10.1212/WNL.0000000000201709

Ejemplares similares

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
por: Baba, Masayuki, et al.
Publicado: (2019)

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients
por: Baba, Masayuki, et al.
Publicado: (2019)

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
por: Baba, Masayuki, et al.
Publicado: (2020)

Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
por: Kim, Kyongsong, et al.
Publicado: (2021)

Mirogabalin, a selective gabapentinoid for managing neuropathic pain—A curtain raiser
por: Nair, Abhijit
Publicado: (2022)

The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids
por: Tang, Hui, et al.
Publicado: (2023)

Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
por: Tetsunaga, Tomoko, et al.
Publicado: (2020)

Mirogabalin and emerging therapies for diabetic neuropathy
por: Javed, Saad, et al.
Publicado: (2018)

Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study
por: Akazawa, Tsutomu, et al.
Publicado: (2021)

Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2022)

Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin
por: Yamanaka, Takuya, et al.
Publicado: (2022)

Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients
por: Kato, Jitsu, et al.
Publicado: (2019)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

A Probable Case of Mirogabalin-Induced Neutropenia
por: Takahashi, Saeko, et al.
Publicado: (2020)

Mirogabalin: could it be the next generation gabapentin or pregabalin?
por: Kim, Jae-Yeon, et al.
Publicado: (2021)

Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation
por: Inage, Kazuhide, et al.
Publicado: (2020)

Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)
por: Misawa, Sonoko, et al.
Publicado: (2023)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

Correction to: Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial
por: Kato, Jitsu, et al.
Publicado: (2020)

Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
por: Doi, Ryoichiro, et al.
Publicado: (2021)

Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study)
por: Kimura, Yoshiyuki, et al.
Publicado: (2021)

T Helper 17 Cells in Autoimmune Liver Diseases
por: Abe, Masanori, et al.
Publicado: (2013)

Alterations of Contralateral Thalamic Perfusion in Neuropathic Pain
por: Ushida, Takahiro, et al.
Publicado: (2010)

Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
por: Sugimoto, Mitsuru, et al.
Publicado: (2021)

Infection as a Risk Factor in the Pathogenesis of Primary Biliary Cirrhosis: Pros and Cons
por: Kumagi, Teru, et al.
Publicado: (2010)

Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages
por: Kiguchi, Norikazu, et al.
Publicado: (2017)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Mirogabalin—A Novel Selective Ligand for the α2δ Calcium Channel Subunit
por: Zajączkowska, Renata, et al.
Publicado: (2021)

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence
por: Chen, Eric Y., et al.
Publicado: (2021)

Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats
por: Kikuchi, Kasumi, et al.
Publicado: (2023)

Plastic changes in amygdala subregions by voluntary running contribute to exercise-induced hypoalgesia in neuropathic pain model mice
por: Kami, Katsuya, et al.
Publicado: (2020)

Editorial
por: Hiasa, Yoichi
Publicado: (2015)

Analgesic characteristics of a newly developed α(2)δ ligand, mirogabalin, on inflammatory pain
por: Komatsu, Shuji, et al.
Publicado: (2021)

Clinical Effectiveness of Mirogabalin Besylate for Trigeminal Neuropathy after Skull Base Surgery: Illustrative Cases
por: Karatsu, Kosuke, et al.
Publicado: (2023)

Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2023)

Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r7bjq8479675hf7cv86m9mugl9